Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: In vivo imaging of the pathologic substrate for premature cardiac death?

Journal of the American College of Cardiology

Volumn 41, Issue 9, 2003, Pages 1568-1572

  Kim, Raymond J ^a   Judd, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

AUTOPSY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG ACCUMULATION; DRUG DISTRIBUTION; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART CONDUCTION; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; HYPERENHANCEMENT; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; IN VIVO STUDY; MYOCARDIAL SCARRING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REPRODUCIBILITY; REVIEW; SCAR FORMATION; SENSITIVITY AND SPECIFICITY; SUDDEN DEATH; TECHNIQUE; TREATMENT OUTCOME;

EID: 0038746921     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00190-6     Document Type: Editorial

References (35)

1. Rehr RB, Peshock RM, Malloy CR, et al. Improved in vivo magnetic resonance imaging of acute myocardial infarction after intravenous paramagnetic contrast agent administration. Am J Cardiol 1986;57:864-8.
2. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
3. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218:215-23.
4. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001;357:21-8.
5. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 2001;104:1101-7.
6. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000;36:1985-91.
7. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105:224-9.
8. Klein C, Nekolla SG, Bengel FM, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002;105:162-7.
9. Wagner A, Mahrholdt H, Holly T, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003;361:374-9.
10. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
11. Lima JA, Judd RM, Bazille A, Schulman SP, Atalar E, Zerhouni EA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms. Circulation 1995;92:1117-25.
12. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-24.
13. Polimeni PI. Extracellular space and ionic distribution in rat ventricle. Am J Physiol 1974;227:676-83.
14. Kim RJ, Choi KM, Judd RM. Assessment of myocardial viability by contrast enhancement. In: Higgins CB, de Roos A, editors. Cardiovascular MRI and MRA. Philadelphia, PA: Lippincott Williams and Wilkins, 2003:209-37.
15. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40:2156-64.
16. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.
17. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979;43:1086-102.
18. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.
19. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84:476-82.
20. Roberts CS, Roberts WC. Morphologic features. In: Zipes DP, Rowlands DJ, editors. Progress in Cardiology. Vol 2/2. Philadelphia, PA: Lea and Febiger, 1989:3-22.
21. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 1992;70:1333-40.
22. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979;128:79-85.
23. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987;60:1340-55.
24. Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561-7.
25. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986;55:575-81.
26. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
27. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
28. Hurwitz JL, Josephson ME. Sudden cardiac death in patients with chronic coronary heart disease. Circulation 1992;85:I43-9.
29. Callans DJ, Josephson ME. Ventricular tachycardia in patients with coronary artery disease. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell To Bedside. Philadelphia, PA: Saunders, 2000:530-6.
30. Saumarez RC, Camm AJ, Panagos A, et al. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 1992;86:467-74.
31. Cripps TR, Counihan PJ, Frenneaux MP, Ward DE, Camm AJ, McKenna WJ. Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:956-61.
32. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989;80:1259-68.
33. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
34. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
35. Mahrholdt H, Wagner A, Holly T, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 2002;106:2322-7.